BACKGROUND: Vitamin D deficiency is related to an increased prevalence of cardiovascular disease. Renin-angiotensin-aldosterone system suppression and vascular dysfunction are considered among the main mechanisms implicated in this association. However, interventional studies demonstrating that vitamin D replacement reduces circulating renin-angiotensin-aldosterone components and improves vascular function in humans are still lacking. METHODS: Thirty-three consecutive patients with essential hypertension and hypovitaminosis D underwent therapy with cholecalciferol 50 000 IU/week orally for 8 weeks. Thirty-three hypertensive patients with normal vitamin D levels and 20 normotensive individuals were also enrolled as control groups. At baseline and at the end of the study, we evaluated plasma renin activity, circulating renin, angiotensin II, aldosterone and plasma vitamin D levels. Endothelial function [flow-mediated dilation (FMD)], carotid-femoral pulse wave velocity and augmentation index, peripheral and central blood pressure were also acquired. RESULTS: After 8-week cholecalciferol administration, all treated patients normalized plasma 25(OH)D values. Furthermore, a reduction in plasma levels of plasma renin activity (1.17 ± 0.3 vs 1.51 ± 0.4 ng/ml per h, P = 0.02), renin (13.4 ± 1.7 vs 19.2 ± 2.9 pg/ml, P < 0.001), angiotensin II (11.6 ± 1.6 vs 15.8 ± 2.7 pg/ml, P = 0.02) was observed at the end of the study. FMD was significantly increased after cholecalciferol treatment (4.4 ± 2.6 vs 3.3 ± 2.1%, P < 0.05), in the absence of changes of brachial artery diameter and endothelium-independent vasodilation. Carotid-femoral pulse wave velocity and augmentation index were not modified, as well peripheral and central blood pressure. CONCLUSION: The restoration of normal vitamin D levels after 8-week cholecalciferol treatment is able to inhibit peripheral renin-angiotensin system and improve FMD in essential hypertensive patients with hypovitaminosis D.
BACKGROUND:Vitamin D deficiency is related to an increased prevalence of cardiovascular disease. Renin-angiotensin-aldosterone system suppression and vascular dysfunction are considered among the main mechanisms implicated in this association. However, interventional studies demonstrating that vitamin D replacement reduces circulating renin-angiotensin-aldosterone components and improves vascular function in humans are still lacking. METHODS: Thirty-three consecutive patients with essential hypertension and hypovitaminosis D underwent therapy with cholecalciferol 50 000 IU/week orally for 8 weeks. Thirty-three hypertensivepatients with normal vitamin D levels and 20 normotensive individuals were also enrolled as control groups. At baseline and at the end of the study, we evaluated plasma renin activity, circulating renin, angiotensin II, aldosterone and plasma vitamin D levels. Endothelial function [flow-mediated dilation (FMD)], carotid-femoral pulse wave velocity and augmentation index, peripheral and central blood pressure were also acquired. RESULTS: After 8-week cholecalciferol administration, all treated patients normalized plasma 25(OH)D values. Furthermore, a reduction in plasma levels of plasma renin activity (1.17 ± 0.3 vs 1.51 ± 0.4 ng/ml per h, P = 0.02), renin (13.4 ± 1.7 vs 19.2 ± 2.9 pg/ml, P < 0.001), angiotensin II (11.6 ± 1.6 vs 15.8 ± 2.7 pg/ml, P = 0.02) was observed at the end of the study. FMD was significantly increased after cholecalciferol treatment (4.4 ± 2.6 vs 3.3 ± 2.1%, P < 0.05), in the absence of changes of brachial artery diameter and endothelium-independent vasodilation. Carotid-femoral pulse wave velocity and augmentation index were not modified, as well peripheral and central blood pressure. CONCLUSION: The restoration of normal vitamin D levels after 8-week cholecalciferol treatment is able to inhibit peripheral renin-angiotensin system and improve FMD in essential hypertensivepatients with hypovitaminosis D.
Authors: Agnieszka Rusińska; Paweł Płudowski; Mieczysław Walczak; Maria K Borszewska-Kornacka; Artur Bossowski; Danuta Chlebna-Sokół; Justyna Czech-Kowalska; Anna Dobrzańska; Edward Franek; Ewa Helwich; Teresa Jackowska; Maria A Kalina; Jerzy Konstantynowicz; Janusz Książyk; Andrzej Lewiński; Jacek Łukaszkiewicz; Ewa Marcinowska-Suchowierska; Artur Mazur; Izabela Michałus; Jarosław Peregud-Pogorzelski; Hanna Romanowska; Marek Ruchała; Piotr Socha; Mieczysław Szalecki; Mirosław Wielgoś; Danuta Zwolińska; Arkadiusz Zygmunt Journal: Front Endocrinol (Lausanne) Date: 2018-05-31 Impact factor: 5.555
Authors: Virna Margarita Martín Giménez; Felipe Inserra; Carlos D Tajer; Javier Mariani; León Ferder; Russel J Reiter; Walter Manucha Journal: Life Sci Date: 2020-05-15 Impact factor: 5.037
Authors: Pedro Henrique Franca Gois; Martin Wolley; Dwarakanathan Ranganathan; Antonio Carlos Seguro Journal: Int J Environ Res Public Health Date: 2018-08-17 Impact factor: 3.390
Authors: Satyesh K Sinha; Ling Sun; Michelle Didero; David Martins; Keith C Norris; Jae Eun Lee; Yuan-Xiang Meng; Jung Hye Sung; Michael Sayre; Maria Beatriz Carpio; Susanne B Nicholas Journal: Nutrients Date: 2022-08-14 Impact factor: 6.706
Authors: Felipe Esdras Lucas Cardoso; Leandro da Cruz Melgaço Dos Santos; Adirlene Pontes de Oliveira Tenório; Matheus Rodrigues Lopes; Romero Henrique de Almeida Barbosa Journal: J Vasc Bras Date: 2020-07-06
Authors: León Ferder; Virna Margarita Martín Giménez; Felipe Inserra; Carlos Tajer; Laura Antonietti; Javier Mariani; Walter Manucha Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-09-30 Impact factor: 5.464